Openbookopenbook
Equity
ImmuPharma PLC(IMM)
GBX --+0.00%
Reward29Low
Risk80High
📊75%Data
Revenue growing 47% YoY
IMM
+0.0 · +0.00%
GBX · LSE
ImmuPharma PLC | Healthcare
Capital Destroyer
Market Cap:36.70M
ℹ️
Reward Rating
29
Low
Bottom 1% (model universe)
75% data coverage
ℹ️
Risk Rating
80
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on IMM to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 5p.

What is ImmuPharma PLC?

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom.

IMM · Verdict

Limited reward · high risk

IMM has limited near-term tailwinds — cash flow and volatility weigh on the model output.

Based on 88% data coverage

IMM · Verdict

What’s working & what to watch

Watchouts 5

  • Cash flow5/100

    Weak vs peers

  • Volatility5/100

    Weak vs peers

  • Profitability10/100

    -260% return on equity

  • Growth17/100

    Earnings -32.8% CAGR

  • Balance sheet44/100

    Current ratio 0.58

Model-based scoring. For information only — not financial advice.

What is ImmuPharma PLC?

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 36.70M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (29)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap36.70M
P/E RatioN/A
Dividend YieldN/A
52 Week High19.4
52 Week Low1.3861
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding503M
No. of Employees6
IndustryBiotechnology
ExchangeLSE
Beta3.019
CurrencyGBX · Reports in GBP
Websitewww.immupharma.co.uk
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.